Hong Yu Ah, Kim Hyung Duk, Jo Kwanhoon, Park Yun Kyung, Lee Jonghoon, Sun In O, Chung Byung Ha, Park Cheol Whee, Yang Chul Woo, Choi Bum Soon
From the Division of Nephrology, Department of Internal Medicine, College of Medicine, The Catholic University of Korea, Seoul, Korea.
Exp Clin Transplant. 2014 Apr;12(2):152-5. doi: 10.6002/ect.2013.0003. Epub 2013 May 29.
Cardiovascular disease is the most common cause of sickness and death for long-term kidney transplant recipients, and dyslipidemia is an important risk factor for developing cardiovascular disease. Lipid-lowering strategies, with the use of statins, have been shown to reduce the cardiovascular risks related to dyslipidemia, but concomitant use of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors and immunosuppressive agents may increase the risk of rhabdomyolysis owing to a drug-drug interaction. We report a case of simvastatin-induced rhabdomyolysis and acute kidney injury triggered by addition of sirolimus and cisplatin-based chemotherapy to a kidney transplant recipient who had previously tolerated chronic statin therapy.
心血管疾病是长期肾移植受者患病和死亡的最常见原因，而血脂异常是发生心血管疾病的重要危险因素。使用他汀类药物的降脂策略已被证明可降低与血脂异常相关的心血管风险，但同时使用3-羟基-3-甲基戊二酰辅酶A还原酶抑制剂和免疫抑制剂可能会因药物相互作用而增加横纹肌溶解的风险。我们报告了一例肾移植受者在先前耐受慢性他汀类药物治疗的情况下，因添加西罗莫司和顺铂类化疗药物而引发的辛伐他汀诱导的横纹肌溶解和急性肾损伤病例。
